Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474178 | 0.86 | — | — | |
| SCHEMBL20768364 | 0.86 | KDM4E (0.57) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28356491 | 0.84 | — | — | |
| Hydrogen Sulfide SCHEMBL19359044 | 0.84 | — | — | |
| SCHEMBL10545165 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL3979349 | 0.84 | — | — | |
| SCHEMBL22361778 | 0.84 | KDM4E (0.55) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL10545704 | 0.84 | — | — | |
| SCHEMBL6807203 | 0.79 | ADRA1A (0.36) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| Cysteamine SCHEMBL19359042 | 0.77 | PAOX (0.56) | KDM4EMAPK1HIF1ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111683684-B | Methods for treating cysteamine-sensitive disorders | 硫创治疗公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117599029-A | Compositions for controlled release of cysteamine and systematic treatment of cysteamine-sensitive disorders | 硫创治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11786491-B2 | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230190683-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11612576-B2 | Methods for the treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20220040127-A1 | COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-11173135-B2 | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200268692-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | Prochimia Surfaces SP. Z.o.o. (PL) | 2020-08-27 | — | — | US | disclosed |
| US-20190070132-A1 | COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | THIOGENESIS THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612576-B2 | Methods for the treatment of cysteamine sensitive disorders | CTH, CBS, SLC19A1 | KDM4E 4265/4885MAPK1 4749/4885HIF1A 2746/4885 |
| US-20200268692-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | CTH, CBS, SLC19A1 | KDM4E 4265/4885MAPK1 4749/4885HIF1A 2746/4885 |
| US-20230190683-A1 | METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS | CTH, CBS, SLC19A1 | KDM4E 4265/4885MAPK1 4749/4885HIF1A 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.